公开(公告)号：EP4415821A1

公开(公告)日：2024-08-21

申请号：EP22880543.8

申请日：2022-10-14

Applicant: TRIGONE PHARMA LTD.

Inventor： GORDON, Avigdor ,  MALCHI, Nadav ,  NASSER, Taher ,  TOUITOU, Dan

IPC: A61P13/00 ,  A61K47/10 ,  A61K47/32

CPC classification number: A61K47/10 ,  A61K47/32 ,  A61P13/00 ,  A61K9/0034 ,  A61K9/0024 ,  A61K9/08 ,  A61K47/42 ,  A61K47/38 ,  A61K47/36 ,  A61K47/34 ,  A61K9/06

公开(公告)号：EP4374917A3

公开(公告)日：2024-07-31

申请号：EP24166404.4

申请日：2018-04-13

Applicant: Massachusetts Institute Of Technology ,  The General Hospital Corporation

Inventor： Li, Xiang ,  Cima, Michael J. ,  Eisner, Brian H.

IPC: A61K31/415 ,  A61K31/24 ,  A61K31/44 ,  A61P13/00

CPC classification number: A61K45/06 ,  A61K31/415 ,  A61K31/4409 ,  A61K31/4422 ,  A61K31/635 ,  A61K9/0034 ,  A61P13/00

Abstract: Provided are formulations and methods for treating one or more genitourinary conditions. The formulations may include a therapeutic agent that includes a calcium channel blocker, a rho kinase inhibitor, or a combination thereof. The methods may include locally administering a therapeutic agent into a ureter. Systems for delivering a therapeutic agent also are provided.

公开(公告)号：EP4397654A1

公开(公告)日：2024-07-10

申请号：EP22863626.2

申请日：2022-09-02

Applicant: Wuhan Humanwell Innovative Drug Research and Development Center Limited Company

Inventor： ZHANG, Xuejun ,  YUE, Yang ,  ZANG, Yang ,  LEI, Sijun ,  XIA, Qingfeng ,  LI, Yuan ,  LIU, Zhe ,  YANG, Jun ,  LI, Li'e

IPC: C07D231/20 ,  A61K31/415 ,  A61P35/00 ,  A61P29/00 ,  A61P19/02 ,  A61P15/00 ,  A61P3/00 ,  A61P13/10

CPC classification number: A61K31/415 ,  A61P3/00 ,  A61P13/00 ,  A61P13/10 ,  A61P15/00 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  C07D231/20

Abstract: An EP4 antagonist represented by formula I, which specifically comprises a crystal form thereof, a pharmaceutically acceptable salt or crystal form thereof, a preparation method therefor, a composition containing same, and a medical use of a related compound. The structure of formula I is shown below:

公开(公告)号：EP4378921A1

公开(公告)日：2024-06-05

申请号：EP22848576.9

申请日：2022-07-27

Applicant: Institute of Basic Medical Sciences Chinese Academy of Medical Sciences

Inventor： JIANG, Chengyu ,  MA, Yiming ,  XU, Longxin

IPC: C07C219/00 ,  C07C229/00 ,  A61K48/00

CPC classification number: A61P17/00 ,  A61P43/00 ,  A61P9/00 ,  A61K47/22 ,  A61K47/10 ,  A61K31/713 ,  A61K9/00 ,  A61K47/12 ,  A61P37/02 ,  A61P1/00 ,  A61P35/00 ,  A61P13/00 ,  A61P31/04 ,  A61P31/12 ,  A61P29/00 ,  A61P31/10 ,  A61P33/00 ,  A61K47/14 ,  A61P25/00 ,  A61P27/02 ,  A61K47/08 ,  A61K47/18 ,  A61K31/7088 ,  C07C219/00 ,  A61K48/00 ,  C07C229/00

Abstract: A use of one or more lipid compounds in the delivery of nucleic acids, and a lipid nucleic acid mixture, pharmaceutical composition or kit comprising the lipid compounds and nucleic acids. The lipid compounds provided above can promote the absorption, particularly oral absorption, of nucleic acids, and promote the entry of nucleic acids into target sites in a subject in need thereof.

公开(公告)号：EP4355356A1

公开(公告)日：2024-04-24

申请号：EP22826003.0

申请日：2022-06-14

Applicant: Yale University

Inventor： KRAPPITZ, Matteus ,  FEDELES, Sorin ,  SOMLO, Stefan

IPC: A61K38/17 ,  A61P1/16 ,  A61P13/00 ,  A61P13/12

CPC classification number: A61P13/12 ,  A61P13/00 ,  A61P1/16 ,  A61K38/00 ,  A61K45/06 ,  A61K31/7064

公开(公告)号：EP3230281A1

公开(公告)日：2017-10-18

申请号：EP15804824.9

申请日：2015-12-07

Applicant: Bayer Aktiengesellschaft

Inventor： DAVENPORT, Adam James ,  BRAEUER, Nico ,  FISCHER, Oliver Martin ,  ROTGERI, Andrea ,  ROTTMANN, Antje ,  NEAGOE, Ioana ,  NAGEL, Jens ,  GODINHO-COELHO, Anne-Marie

IPC: C07D417/12 ,  C07D417/14 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/433 ,  A61P13/00 ,  A61P29/00 ,  A61P31/18 ,  A61P25/16 ,  A61P25/28

CPC classification number: C07D417/12 ,  A61K31/5377 ,  A61P13/00 ,  A61P13/10 ,  A61P25/16 ,  A61P25/28 ,  A61P29/00 ,  A61P31/04 ,  A61P31/18 ,  C07D417/14 ,  C07D471/08 ,  C07D498/08 ,  Y02P20/582

Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.

Abstract translation: 本发明涉及如本文所述和定义的通式（I）的1,3-噻唑-2-基取代的苯甲酰胺化合物，包含所述化合物的药物组合物和组合以及涉及所述化合物在制备用于 治疗或预防作为单独药剂或与其他活性成分组合的疾病，特别是神经原性疾病。

公开(公告)号：EP3756656B1

公开(公告)日：2024-09-11

申请号：EP20172705.4

申请日：2012-03-30

IPC: A61K9/19 ,  A61K38/48 ,  A61K47/02 ,  A61K47/26 ,  A61K47/20 ,  A61P1/00 ,  A61P1/06 ,  A61P13/00 ,  A61P13/10 ,  A61P17/00 ,  A61P21/00 ,  A61P25/06 ,  A61P27/02

CPC classification number: C12Y304/24069 ,  A61K47/02 ,  A61K47/26 ,  A61K38/4893 ,  A61K9/19 ,  A61K47/20 ,  A61P1/00 ,  A61P1/06 ,  A61P13/00 ,  A61P13/10 ,  A61P17/00 ,  A61P21/00 ,  A61P25/06 ,  A61P27/02 ,  Y02A50/30

公开(公告)号：EP3823645B1

公开(公告)日：2024-07-03

申请号：EP19841655.4

申请日：2019-07-22

IPC: A61K35/28 ,  A61P13/00 ,  A61K35/33 ,  A61K35/35 ,  A61K35/38 ,  A61K35/545 ,  A61K35/15 ,  A61K35/17 ,  A61K35/18 ,  A61K35/19

CPC classification number: A61P13/00 ,  A61K35/28 ,  A61K35/545 ,  A61K35/35 ,  A61K35/38 ,  A61K35/33 ,  A61K35/15 ,  A61K35/19 ,  A61K35/18 ,  A61K35/17

公开(公告)号：EP4377300A1

公开(公告)日：2024-06-05

申请号：EP22754142.2

申请日：2022-07-26

Applicant: The University of Manchester

Inventor： BUTTERWORTH, Samuel ,  GARZON SANZ, Miguel

IPC: C07D295/22 ,  C07D295/10 ,  C07D249/06 ,  C07D491/08 ,  C07D405/12 ,  C07C275/28 ,  A61K31/445 ,  A61K31/4453 ,  A61K31/4192 ,  A61K31/5386 ,  A61K31/4035 ,  A61K31/34 ,  A61P3/00 ,  A61P3/06 ,  A61P3/10

CPC classification number: C07D295/22 ,  C07D295/10 ,  C07D249/06 ,  C07D491/08 ,  C07D405/12 ,  A61P3/00 ,  A61P3/06 ,  A61P3/10 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P35/00 ,  A61P35/02 ,  A61P1/00 ,  A61P1/04 ,  A61P1/16 ,  A61P29/00 ,  A61P17/00 ,  A61P17/06 ,  A61P19/00 ,  A61P19/02 ,  A61P13/00 ,  A61P13/12 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  C07C317/42

公开(公告)号：EP4374917A2

公开(公告)日：2024-05-29

申请号：EP24166404.4

申请日：2018-04-13

Applicant: Massachusetts Institute Of Technology ,  The General Hospital Corporation

Inventor： Li, Xiang ,  Cima, Michael J. ,  Eisner, Brian H.

IPC: A61P13/00

CPC classification number: A61K45/06 ,  A61K31/415 ,  A61K31/4409 ,  A61K31/4422 ,  A61K31/635 ,  A61K9/0034 ,  A61P13/00

Abstract: Provided are formulations and methods for treating one or more genitourinary conditions. The formulations may include a therapeutic agent that includes a calcium channel blocker, a rho kinase inhibitor, or a combination thereof. The methods may include locally administering a therapeutic agent into a ureter. Systems for delivering a therapeutic agent also are provided.